Trevi Therapeutics (TRVI) Fundamental Analysis: Revenue, Earnings & Valuation

1.54 / 10

Underperform

Fundamental rating is Underperform with a 1.5/10 score. Revenue growth is strong (134% YoY), but inventory turnover, AR turnover and interest coverage are modest, and tax ratio and fixed‑asset turnover are poor. Overall financial health appears guarded.

Analysis Checks(6/10)

Revenue-MV

Value-0.08

Score3/3

Weight63.07%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value134.75

Score2/3

Weight3.35%

1M Return0.58%

Inventory turnover ratio

Value106.57

Score3/3

Weight-3.58%

1M Return-0.67%

Accounts receivable turnover ratio

Value23.61

Score2/3

Weight-3.55%

1M Return-0.65%

PB-ROE

Value5.19

Score0/3

Weight25.93%

1M Return3.80%

Income tax / Total profit (%)

Value0.15

Score1/3

Weight-3.25%

1M Return-0.59%

Fixed assets turnover ratio

Value9771.06

Score1/3

Weight-6.65%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-4.00%

1M Return-0.73%

Cost of sales ratio (%)

Value57.03

Score2/3

Weight-3.93%

1M Return-0.74%

Asset-MV

Value-0.55

Score0/3

Weight32.61%

1M Return4.88%

Is TRVI undervalued or overvalued?

TRVI scores 1.54/10 on fundamentals and holds a Premium valuation at present. Backed by its -30.23% ROE, 0.00% net margin, -34.61 P/E ratio, 8.07 P/B ratio, and 31.91% earnings growth, these metrics solidify its Underperform investment rating.